Childhood heart diseases refer to a range of congenital and acquired conditions affecting the heart in children. While some heart issues may be present at birth, others can develop during childhood due to various factors. Congenital heart defects, structural abnormalities present at birth, are among the most common forms of childhood heart diseases. These defects can affect the heart's valves, chambers, or blood vessels, compromising its ability to pump blood effectively. Acquired heart conditions in children may result from infections, inflammatory disorders, or complications from other health issues. Timely diagnosis and medical intervention are crucial to manage childhood heart diseases, as they can significantly impact a child's overall well-being and development. Advances in medical technology and surgical techniques have improved the prognosis for many children with heart conditions, highlighting the importance of early detection and comprehensive medical care in addressing these challenges. Regular check-ups and a collaborative approach between healthcare professionals and families are essential for managing childhood heart diseases and improving the quality of life for affected children.
Title : Frequency of residual risk in cardiovascular secondary prevention in patients treated at the Reina Fabiola University Clinic
Agustin Joison, Cordoba Catholic University, Argentina
Title : Revolutionizing heart health through Personalized & Precision Medicine (PPM): Towards personalized cardiovascular prevention, precision cardiac care & rehabilitation via optimizing Cardiac Hospital Networks
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Antibody-proteases as unique biomarkers, potential targets and translational tools of the next step generation to be used in personalized and precision cardiology practice
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Investigation of bergapten’s pharmacological activity against doxorubicin induced cardiotoxicity: supporting evidence from cellular and animal models
Bijoy Krishna Banik, National Institute of Pharmaceutical Education and Research (NIPER)-Guwahati, India